VARDITRA – Potency Remedy | Buy in Ukraine with Delivery

What is VARDITRA?

VARDITRA is a medicinal product belonging to the pharmacological group of selective phosphodiesterase type 5 (PDE-5) inhibitors. The primary purpose of the medication is to restore and maintain erectile function in men suffering from erectile dysfunction of various origins. The manufacturer of VARDITRA ensures high quality of the active substance and finished dosage form in accordance with international Good Manufacturing Practice (GMP) standards. The drug is produced in the form of film-coated tablets, which provides convenience for oral administration and precise dosing.

The mechanism of action of VARDITRA is based on the selective inhibition of the phosphodiesterase type 5 enzyme, which is responsible for the breakdown of cyclic guanosine monophosphate (cGMP) in the cavernous bodies of the penis. Due to this action, cGMP accumulates, promoting the relaxation of vascular smooth muscle and increasing arterial blood flow to the corpora cavernosa. It is important to understand that VARDITRA works only in the presence of natural sexual stimulation, as it triggers the cascade of biochemical reactions necessary for an erection. The medication is not a hormonal agent and does not affect libido or testosterone levels in the body.

VARDITRA has established itself as an effective remedy with a predictable therapeutic profile, allowing its use across various age groups of men. The drug features a rapid onset of action and sufficient duration of effect, enabling patients to plan sexual activity without unnecessary psychological stress. Clinical studies have confirmed the high efficacy of VARDITRA even in patients with concomitant conditions such as diabetes mellitus or arterial hypertension. Before starting therapy, it is mandatory to consult a doctor to rule out potential contraindications and determine the optimal dosage.

What is VARDITRA prescribed for?

The main indication for the use of VARDITRA is erectile dysfunction, defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. This condition can have an organic, psychogenic, or mixed origin, and VARDITRA demonstrates efficacy in all of these cases. The medication helps restore patient self-confidence, reduces performance anxiety associated with fear of failure, and improves the overall quality of intimate life. Doctors also prescribe VARDITRA to men who have developed erectile dysfunction against the background of chronic stress or fatigue.

VARDITRA is used in the complex treatment of patients with diabetes mellitus, as diabetic angiopathy and neuropathy frequently lead to impaired erectile function. In such cases, the drug helps compensate for vascular and nerve disorders, improving the engorgement of the cavernous bodies even in the presence of microangiopathies. The efficacy of VARDITRA in diabetic patients is supported by numerous clinical observations, making it a drug of choice for this category of patients. An additional advantage is the absence of a negative impact on glycemic control and the possibility of combining it with blood glucose-lowering medications.

Another important indication for prescribing VARDITRA is erectile dysfunction following surgical interventions on pelvic organs, particularly after radical prostatectomy for prostate cancer. In these patients, the preservation of neurovascular bundles does not always guarantee complete recovery of erection, making pharmacological support an essential component of rehabilitation. VARDITRA promotes the gradual restoration of natural erectile mechanisms and prevents the development of cavernous tissue fibrosis. The drug may also be recommended to men with erectile dysfunction caused by taking certain medications, following consultation with a doctor regarding possible adjustments to baseline therapy.

Composition and active ingredients of VARDITRA

The active substance in VARDITRA is vardenafil in the form of hydrochloride trihydrate, which ensures optimal bioavailability and stability of the molecule during oral administration. Vardenafil belongs to highly selective phosphodiesterase type 5 inhibitors, which accounts for its targeted effect specifically on the vessels of the cavernous bodies. The selectivity of vardenafil for PDE-5 significantly exceeds its activity against other phosphodiesterase isoenzymes, minimizing the risk of systemic side effects. The concentration of the active substance in the blood reaches a therapeutic level as early as 25–40 minutes after taking the tablet.

Excipients of VARDITRA include microcrystalline cellulose, crospovidone, magnesium stearate, and hypromellose, which ensure the appropriate technological properties of the tablet mass. The film coating consists of hypromellose, titanium dioxide, macrogol, and colorants, which give the tablet its characteristic appearance and protect the active substance from premature degradation. The inactive ingredients do not exert independent pharmacological action but ensure product stability throughout its shelf life. The composition of VARDITRA is designed to ensure uniform release of vardenafil in the gastrointestinal tract and predictable pharmacokinetics.

The mechanism of action of vardenafil is mediated through the inhibition of the PDE-5 enzyme, preventing the degradation of cyclic guanosine monophosphate in the vascular smooth muscle cells of the penis. The accumulation of cGMP activates protein kinase G, triggering a cascade of reactions that lead to a decrease in intracellular calcium concentration and relaxation of smooth muscle. This provides arterial dilation and increased blood flow to the cavernous bodies, clinically manifesting as a firm erection. Importantly, VARDITRA does not induce an erection without sexual stimulation, as stimulation is required to initiate the release of nitric oxide from the vascular endothelium.

Dosing of VARDITRA

The standard recommended starting dose of VARDITRA for adult men is 10 mg per single administration, taken approximately 25–60 minutes before planned sexual activity. Depending on individual response and tolerability, the dose may be increased to a maximum of 20 mg or decreased to 5 mg. The maximum recommended frequency of administration is once daily, as exceeding this frequency does not increase efficacy but raises the risk of adverse reactions. Dose adjustment is generally not required for elderly patients; however, starting therapy with the lowest effective dose is recommended.

For patients with mild to moderate hepatic impairment, the initial dose of VARDITRA should not exceed 5 mg, and if necessary, it can be gradually increased under medical supervision. In severe hepatic impairment, the use of the drug is contraindicated due to a lack of sufficient safety data. Men with mild to moderate renal impairment do not require dose adjustment, whereas in severe renal impairment, it is recommended to limit the dosage to a minimum of 5 mg. Concomitant use with CYP3A4 inhibitors requires reducing the VARDITRA dose to 5 mg with an interval of no more than once every 72 hours.

The duration of a treatment course with VARDITRA is determined individually depending on the cause of erectile dysfunction and the dynamics of the clinical response. The drug can be used either situationally, immediately before expected sexual contact, or as a course of treatment to restore confidence and train the vascular mechanisms of erection. Regular intake should not exceed once per day, and the overall duration of therapy typically ranges from a few weeks to several months. Once a stable therapeutic effect is achieved, the physician may recommend a gradual dose reduction or switching to on-demand use.

How to take VARDITRA correctly?

VARDITRA should be taken orally with a sufficient amount of water, regardless of food intake; however, it should be noted that high-fat meals may delay the onset of action. It is not recommended to chew or crush the tablet, as this may compromise the integrity of the film coating and alter the pharmacokinetics of the drug. The optimal time of administration is considered to be 25–60 minutes before planned sexual activity, although the therapeutic effect may persist for 4–6 hours after intake. Patients should remember that VARDITRA works only in the presence of sexual stimulation, so mechanical intake of the tablet without the corresponding mood will not result in an erection.

In case of a missed planned dose of VARDITRA, do not double the next dose, as this significantly increases the risk of side effects without a proportional increase in therapeutic action. If a dose was missed and sexual activity is no longer planned, the next dose should be taken according to the usual schedule or before the next expected contact. It is important not to exceed the maximum daily dose of 20 mg and not to combine VARDITRA with other PDE-5 inhibitors. Patients with cardiovascular diseases must undergo an evaluation prior to therapy to assess the safety of physical exertion associated with sexual activity.

While taking VARDITRA, grapefruit juice consumption should be avoided, as it contains substances that inhibit the CYP3A4 enzyme and can increase vardenafil concentrations in the blood. This may lead to an exacerbation of side effects such as headache, dizziness, or facial flushing. It is also not recommended to combine the drug with excessive alcohol consumption, as ethanol can reduce erectile ability and aggravate orthostatic hypotension. Before starting VARDITRA, be sure to consult a physician, as individual responses may vary depending on age, comorbidities, and other factors.

Side effects of VARDITRA

The most common side effects of VARDITRA are headache, facial flushing, nasal congestion, and dyspeptic disorders, which occur as a result of vasodilation and smooth muscle relaxation. These symptoms are usually mild to moderate, appear within the first hours after taking the medication, and resolve spontaneously without additional treatment. The frequency of their occurrence depends on the dose, so if pronounced discomfort appears, it is recommended to reduce the dose after consulting a physician. Most patients tolerate VARDITRA well, and adverse events rarely require discontinuation of the drug.

Uncommon side reactions of VARDITRA include dizziness, visual disturbances, increased sensitivity to light, back pain, and myalgia. Visual disturbances are associated with a minor effect of vardenafil on phosphodiesterase type 6 present in the retina and typically manifest as mild changes in color perception or increased light sensitivity. These symptoms are temporary and disappear as the drug is eliminated from the body. Patients experiencing marked dizziness or visual impairment should refrain from driving vehicles until symptoms fully resolve.

Rare but potentially serious side effects of VARDITRA include priapism — a prolonged and painful erection lasting more than 4 hours — as well as sudden loss of vision or hearing. If priapism occurs, immediate medical attention is required, as lack of timely treatment can lead to irreversible damage to cavernous tissue. You should also immediately stop taking the drug and consult a doctor if you experience chest pain, heart rhythm disturbances, or severe hypotension. Individual reactions to VARDITRA may vary, so any unusual symptoms require medical evaluation.

Contraindications of VARDITRA

An absolute contraindication to the use of VARDITRA is the concomitant administration of nitrates or nitric oxide donors in any dosage form, as such a combination can cause a life-threatening drop in blood pressure. The drug is also contraindicated in patients with hypersensitivity to vardenafil or any excipient of the tablet. Severe hepatic impairment, end-stage renal disease, and conditions in which sexual activity is inadvisable are also absolute contraindications. These conditions include recent myocardial infarction, stroke, unstable angina, and severe arterial hypotension.

VARDITRA is not prescribed to patients with hereditary degenerative retinal disorders, including retinitis pigmentosa, due to a theoretical risk of worsening visual impairment. The drug is contraindicated in men who have lost vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether it was associated with prior PDE-5 inhibitor use. Relative contraindications include anatomical penile deformations and conditions that increase the risk of priapism, such as sickle cell anemia, leukemia, or multiple myeloma. In such cases, the decision to prescribe VARDITRA is made by a physician after a careful risk-benefit assessment.

VARDITRA is not intended for use in women, children, and adolescents under 18 years of age, as safety and efficacy in these groups have not been studied. In elderly men, the drug may be prescribed without mandatory dose adjustment; however, increased sensitivity to vasodilatory effects and the potential presence of concomitant cardiovascular diseases should be considered. In patients with bleeding disorders or active peptic ulcer disease, VARDITRA should be used with caution due to an increased risk of bleeding. Before starting therapy, be sure to inform your doctor about all existing health conditions and medications you are currently taking.

Interaction of VARDITRA with other drugs and alcohol

VARDITRA is strictly forbidden to be combined with nitrates used to treat angina, as well as with nitric oxide donors such as amyl nitrite or butyl nitrite, as this can lead to a critical drop in blood pressure. CYP3A4 inhibitors, which include ketoconazole, itraconazole, ritonavir, indinavir, and clarithromycin, slow down the metabolism of vardenafil, increasing its concentration in the blood, which requires reducing the dose of VARDITRA to 5 mg. Alpha-blockers used for prostatic hyperplasia may enhance the hypotensive effect, so the combination should be prescribed with caution and only after stabilizing the patient's condition. Other antihypertensive agents do not display clinically significant interactions with VARDITRA; however, blood pressure monitoring remains mandatory.

Alcohol consumption while taking VARDITRA is permissible only in moderate amounts, as excessive ethanol intake can enhance vasodilation and increase the risk of orthostatic hypotension, dizziness, and headache. Alcohol also reduces erectile capacity, which can negate the therapeutic effect of the drug and create a false impression of its inefficacy. VARDITRA does not affect the ability to drive in most patients; however, if dizziness or visual impairment occurs, one should refrain from driving and operating machinery. Patients taking other medications must inform their doctor before starting VARDITRA therapy to avoid potentially dangerous combinations.

Where to buy VARDITRA in Ukraine

VARDITRA is available in pharmacy chains across Ukraine with a doctor's prescription, ensuring controlled and safe use of the drug in accordance with an established diagnosis. You can purchase the medication both at physical retail pharmacies and through online prescription booking services, which allow you to order VARDITRA with delivery or pick-up from the nearest pharmacy. The cost of the medication may vary depending on the dosage, the number of tablets in the package, and the pricing policy of the specific pharmacy chain. Before purchasing, it is recommended to check availability across several pharmacies to select the most favorable offer.

VARDITRA should be stored in a dry, dark place at a temperature not exceeding 25 degrees Celsius, out of the reach of children. The shelf life of the preparation is typically 3 years from the date of manufacture, after which the use of the tablets is strictly prohibited. Do not use VARDITRA if the integrity of the packaging is compromised or if the tablets have changed their appearance. Self-treatment of erectile dysfunction without a prior medical examination is dangerous, as this condition can be an early marker of serious cardiovascular disease; therefore, before using VARDITRA, always consult a physician to establish the exact cause of the disorder and determine a safe treatment strategy.